<DOC>
	<DOCNO>NCT02954939</DOCNO>
	<brief_summary>This study investigate effect mycophenolate mofetil cyclosphosphamide lymphocyte subset patient proliferative lupus nephritis . Patients biopsy-proven Class III/IV+/-V LN randomize receive : 1 ) prednisolone ( 0.8mg/kg/day ) plus CTX ( 1.5-2mg/kg/d ) 6 month ) follow Azathioprine ( AZA ) ( 1-1.5mg/kg/d ) maintenance ; OR 2 ) prednisolone ( 0.8mg/kg/d ) plus MMF ( 1g bd ) 6 month , follow MMF ( taper accord clinical status ) maintenance . The lymphocyte subset serum cytokine profile measure 4- , 12- , 24- , 36- 48 week induction treatment . The lymphocyte subset serum cytokine profile compare two treatment regimen , also correlate subsequent risk relapse .</brief_summary>
	<brief_title>The Effect Mycophenolate Mofetil Cyclophosphamide Lymphocyte Subsets Patients With Proliferative Lupus Nephritis</brief_title>
	<detailed_description>This study investigate effect mycophenolate mofetil cyclosphosphamide lymphocyte subset patient proliferative lupus nephritis . Patients biopsy-proven Class III/IV+/-V LN randomize receive : 1 ) prednisolone ( 0.8mg/kg/day ) plus CTX ( 1.5-2mg/kg/d ) 6 month ) follow Azathioprine ( AZA ) ( 1-1.5mg/kg/d ) maintenance ; OR 2 ) prednisolone ( 0.8mg/kg/d ) plus MMF ( 1g bd ) 6 month , follow MMF ( taper accord clinical status ) maintenance . The lymphocyte subset serum cytokine profile measure 4- , 12- , 24- , 36- 48 week induction treatment . The lymphocyte subset serum cytokine profile compare two treatment regimen , also correlate subsequent risk relapse .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Patients biopsy proven Class III/IV+/V LN ( ISN/RPS classification ) active nephritis indicate increase proteinuria &gt; 1g/day and/or rise serum creatinine &gt; 15 % compare baseline , without serological reactivation . 2 . Willing give inform consent 1 . Patients receive calcineurin inhibitor proliferation signal inhibitor maintenance immunosuppression precede 3 month 2 . Patients receive biologics therapy ( e.g . rituximab , abatacept ) precede 12 month 3 . Patients pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>lupus nephritis</keyword>
	<keyword>lymphocyte subset</keyword>
	<keyword>cytokine</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>cyclophosphamide</keyword>
</DOC>